From Toad Venom to Drug Development: The Clinical Pharmacology of Mebufotenin (5-MeO-DMT) in Treatment-Resistant Depression
CNS Drugs · 04.11.2026
DOI: 10.1007/s40263-026-01346-0 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift CNS Drugs, online erschienen am 04.11.2026. Verfasst von Robert Likić und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Department of Internal Medicine, University Hospital Centre Zagreb and School of Medicine, University of Zagreb, K…. Die Arbeit nennt 66 Literaturangaben.
Themen: Depression
Abstract (Originalsprache)
Treatment-resistant depression affects about one-third of patients with major depressive disorder and remains a major unmet need. Mebufotenin (5-methoxy-N,N-dimethyltryptamine; 5-MeO-DMT), the principal psychoactive constituent of Incilius alvarius parotoid secretion and of several Amazonian plants, is a pharmacologically atypical serotonergic psychedelic in clinical development for this indication. This narrative review analyses its clinical pharmacology, drawing on a structured search of PubMed/MEDLINE, EMBASE, Scopus, ClinicalTrials.gov and grey literature through 15 August 2026, supplemented by regulatory and sponsor disclosures. Mebufotenin is a non-selective serotonin agonist with high affinity at 5-hydroxytryptamine receptor 1A (5-HT1A, Ki 3.0 nM) and markedly lower affinity at 5-HT2A, with reported selectivity spanning approximately 30-fold to 300-fold depending on whether the 5-HT2A receptor is agonist- or antagonist-labelled. Clearance is dominated by monoamine oxidase A; the cytochrome P450 2D6 (CYP2D6)-derived metabolite bufotenine has a receptor profile comparable to the parent compound rather than a distinct 5-HT2A-preferring one, and was below the limit of quantification in the only human study to measure it. In the pivotal phase 2b trial (GH001-TRD-201), inhaled GH001 produced a day 8 placebo-adjusted Montgomery-Åsberg Depression Rating Scale (MADRS) reduction of - 15.5 points (p < 0.001; d = - 2.0) and day 8 remission in 23/40 (57.5%) versus 0/41 (0%) with placebo, with 20/23 (87.0%) day 8 remitters in remission at 6 months under as-needed retreatment and no serious treatment-related adverse events. Median psychoactive duration was 9.0-14.0 min across doses, and 97.5% of patients were discharge-ready within 1 h. GH001 has been studied without protocol-mandated psychotherapy, although this does not establish that psychological support is unnecessary. Evidence rests principally on a single randomised trial, and replication in larger, more diverse phase 3 studies with formal blinding-integrity assessment is required.
Autor:innen und Institutionen
- Division of Clinical Pharmacology, Department of Internal Medicine, University Hospital Centre Zagreb and School of Medicine, University of Zagreb, Kišpatićeva 12, 10000, Zagreb, Croatia. robert.likic@kbc-zagreb.hr.
- Centre for Human Drug Research (CHDR), Leiden, The Netherlands.
- Leiden University Medical Center, Leiden, The Netherlands.
- Department of Psychiatry, Aalborg University Hospital, Aalborg, Denmark.
- Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
- Croatian Institute for Health Insurance and University of Zagreb School of Medicine, Zagreb, Croatia.
Zitieren
APA
Likić, R., Radanović, I., Rkman, D., Brnić, S., Jacobs, G., & Groeneveld, G. J. (2026). From Toad Venom to Drug Development: The Clinical Pharmacology of Mebufotenin (5-MeO-DMT) in Treatment-Resistant Depression. CNS Drugs. https://doi.org/10.1007/s40263-026-01346-0
Vancouver
Likić R, Radanović I, Rkman D, Brnić S, Jacobs G, Groeneveld GJ. From Toad Venom to Drug Development: The Clinical Pharmacology of Mebufotenin (5-MeO-DMT) in Treatment-Resistant Depression. CNS Drugs. 2026. doi:10.1007/s40263-026-01346-0
BibTeX
@article{Liki2026,
author = {Likić, Robert and Radanović, Igor and Rkman, Deni and Brnić, Sanja and Jacobs, Gabriel and Groeneveld, Geert Jan},
title = {From Toad Venom to Drug Development: The Clinical Pharmacology of Mebufotenin (5-MeO-DMT) in Treatment-Resistant Depression},
journal = {CNS Drugs},
year = {2026},
doi = {10.1007/s40263-026-01346-0}
}
EUVIMED